

טבלת מחקרים פתוחים לגיוס – טבלה מעודכנת נכון ל- 1/1/2024

MCL	MK 1026-003 Cohort E אריאל	Relapse/refractory MCL prior CIT and BTKi	Nemtabrutinib	Basket phase 2		MSD	3/6
	MK 2140-006 אריאל	Relapse/refractory MCL at least 2 prior LOT including BTKi	Zilovetamab vedotin + Nemtabrutinib	Basket phase 2		MSD	0/3
		Relapse/refractory MCL at least 1 prior LOT	Zilovetamab vedotin + Nemtabrutinib				0/3
MZL	MK 1026-003 Cohort F אריאל	Relapse/refractory MZL prior CIT and BTKi	Nemtabrutinib	Basket phase 2		MSD	3/6
WM	MK 1026-003 אריאל	Relapse/refractory WM prior CIT and BTKi	Nemtabrutinib	Basket phase 2		MSD	3/6
CLL	MK 1026-003 cohort C אריאל	Del 17p/ TP53 Relapse/refractory CLL at least 1 prior LOT	Nemtabrutinib	Basket phase 2	יש לבקש סלוט עבור מטופל לפני שמחתימים על טופס הסכמה	MSD	3/6
	MK 2140-006 אריאל	Relapse/refractory CLL at least 2 prior LOT	Zilovetamab vedotin (2 dose levels)	Phase 2/3		MSD	0/3

MM	XPORT יבגני	Relapse/refractory MM Pentarefractory	Selinexor + steroids	Phase 2		Karyopharma	12/13
	Monumental-4 רעות	Relapse / refractory MM Unexposed to dara	Dara-Pom-Dex vs. Dara-Talquetamab vs. Dara- Pom-Talquetamab	Phase 3		Janssen ICON	3/4
MF	Transform-2 יבגני	Relapse / refractory MF Post ruxolitinib	Navitoclax + ruxolitinib vs. Best available therapy	RCT Phase 3		Abbvie	2/3
MDS	Registry דועגא	Newly diagnosed MDS patients UP to 6 months from dx	Non interventional	prospective Israeli registry		משה מיטלמן - איכילוב	10/20
wAIHA	VAY736 יריב	patients who failed at least one line of treatment	ianalumab (VAY736) versus placebo	phase 3	Sep 2025	Novartis	0/1
	MOM-M281- 006(Energy) יריב	patients who failed at least one line of treatment	Nipocalimab versus placebo	Phase 2/3		Janssen	1/2